CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Cryoablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01307501
NCT01307501N/ACompleted
CompareCT.gov

Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy

Boston Scientific Corporation·interventional·Posted Mar 3, 2011·Updated Jul 19, 2021

In Brief

A clinical study evaluating Cryoablation for Metastatic Lung Cancer. Completed, enrolled 40 participants across 4 sites in 2 countries.

Detailed Summary

ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Lung Cancer
CountriesFrance, United States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 3, 2011
Enrollment StartJan 4, 2012
Primary CompletionAug 30, 2018
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 15.3 years ago

Interventions

Cryoablationdevice

Application of extremely cold temperatures to the identified tumor(s).